Nava.Dh

NAVA.DH's capital structure is heavily leveraged, with a debt-to-equity ratio of 5.4, indicating a high reliance on debt financing. The company's liquidity position is moderate, as evidenced by a current ratio of 2.23, suggesting it can cover its short-term obligations but with limited buffer. The company's free cash flow of 98,416,420 BDT indicates some capacity to fund operations and reduce debt, although the operating cash flow of 6,924,050 BDT is relatively low.

In terms of profitability, NAVA.DH reported a net income of 7,265,550 BDT, but its operating income was negative at -10,148,660 BDT, indicating operational inefficiencies. The return on equity of 0.0031 and return on assets of 0.0005 are significantly below industry benchmarks, suggesting poor capital utilization and asset efficiency.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases its exposure to regional economic fluctuations. There is no information on specific geographic markets or revenue distribution by region, making it difficult to assess the extent of geographic risk.

NAVA.DH's growth trajectory is uncertain, as the company's recent revenue of 4,480,592,390 BDT is below the analyst estimate of 5,024,180,000 BDT, indicating potential underperformance. The company's capital expenditure of -173,304,950 BDT suggests a reduction in investment, which could impact long-term growth prospects.

The company faces moderate liquidity risk due to its high debt levels and limited cash reserves, with cash and equivalents amounting to 202,433,320 BDT. The risk assessment indicates a low dilution potential, but the negative net cash position after subtracting total debt is a key flag that could affect investor confidence.

Recent events, including the latest financial filing, show a mixed performance with a net income but a negative operating income, which may raise concerns among investors and analysts. There are no disclosed recent transcripts or additional filings that provide further insight into the company's strategic direction or operational changes.

Navamedic ASA (NAVA) has undergone a complete leadership overhaul, with the addition of a new CEO and two new Board members alongside the departure of the former CEO and two outgoing Board members. This significant management event, detected on July 16, 2026, represents a notable shift in the company's governance structure, marking a fresh start for the organization's executive and oversight teams. The restructuring involves the appointment of a new Chief Executive Officer to lead the company's operations, supported by the integration of two new individuals into the Board of Directors. Concurrently, the previous CEO and two existing Board members have stepped down from their roles, indicating a deliberate transition in strategic direction and corporate stewardship. This change is particularly material given Navamedic's current profile, which includes a single officer and no analyst coverage, index membership, or identified top holders. The absence of prior financial analysis or market tracking for the ticker means this leadership reset establishes the foundational management team for future corporate developments and potential market engagement. As this is the first analysis for Navamedic ASA, there is no prior basis for computing deltas in performance or sentiment. The significance of these management changes lies in their role as the initial benchmark for the company's governance, setting the stage for future operational execution and strategic decision-making under the new leadership.

Revenue grew at a 19.4% CAGR over four years, demonstrating strong top-line expansion momentum.

Analysts project 38.7% upside to a consensus price target of 26.0 NOK, signaling bullish sentiment.

Gross profit increased to 220.3 million NOK in FY2026, indicating improving core profitability before operating expenses.

Free cash flow turned positive at 5.4 million NOK in FY2026, recovering from a negative position in FY2024.

Capex intensity is above the 75th percentile of peers, suggesting significant investment in future growth drivers.

Debt-to-equity ratio stands at 1.89, classified as high leverage, increasing financial risk and interest burden.

Return on equity is -9.14%, placing the company in the bottom quartile of its pharmaceutical peer cohort.

Operating margin of 0.82% remains significantly below the 5.6% median for the pharmaceutical sector.

Current ratio of 0.46 indicates potential liquidity constraints, as current assets cover less than half of current liabilities.